Asia-Pacific Drug Delivery Devices Market – Industry Trends and Forecast to 2030

Asia-Pacific Drug Delivery Market, By Product Type (Oral Drug Delivery, Pulmonary Drug Delivery, Injectable Drug Delivery, Ophthalmic Drug Delivery, Nasal Drug Delivery, Topical Drug Delivery, Implantable Drug Delivery, Transmucosal Drug Delivery), Application (Cancer, Diabetes, Respiratory Diseases, Cardiovascular Diseases, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2030.

Asia-Pacific Drug Delivery Market Analysis and Size

In recent years, the drug delivery market is anticipated to proliferate during the forecast period. According to the World Health Organization (WHO), chronic disease prevalence is expected to rise by 57% by the end of 2020, according to the World Health Organization (WHO). The desire for healthcare systems to focus more on advanced drug delivery technologies has risen rapidly in response to the rise in chronic diseases. Furthermore, there is a growing emphasis on product safety, efficacy, and patient-friendliness. The drug delivery market would increase in the approaching years due to the demand for sophisticated technologies to meet the rising demand for routine injectable pharmaceuticals to treat chronic illnesses.                       

Data Bridge Market Research analyses that the Asia-Pacific drug delivery market, which was USD 1,582.14 million in 2022, is expected to USD 3,038.66  million by 2030, and is expected to undergo a CAGR of 8.50% during the forecast period of 2023 to 2030. This oral drug delivery segment dominates the product type segment of the drug delivery market owing to the advancements in technology. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Asia-Pacific Drug Delivery Market Scope and Segmentation

Market Definition

Drug delivery introduces a therapeutic effect in a human's body by providing a drug to a certain targeted place. The safety and efficacy can be increased by adjusting the rate, time, and release of the drug in the body. Drugs can be delivered in a variety of ways, including oral, injectable, pulmonary, nasal, and other routes. The features of nanoparticles have been studied and used to develop drug delivery systems, which has made the process of drug distribution more efficient and time-saving.

Asia-Pacific Drug Delivery Market Dynamics

Drivers

• Increasing Prevalence of Chronic Diseases

The rising prevalence of chronic diseases, such as diabetes, cancer, cardiovascular diseases, and respiratory disorders, is driving the demand for effective drug delivery systems. These systems help in targeted drug delivery, improving treatment outcomes and patient compliance.

• Technological Advancements

Advancements in drug delivery technologies, such as nanotechnology, microencapsulation, and 3D printing, have revolutionized the field. These advancements have led to the development of novel drug delivery systems that offer enhanced drug stability, controlled release, and improved bioavailability.

• Growing Demand for Self-Administration

There is a growing trend towards self-administration of medications, especially for chronic conditions. Drug delivery systems that are easy to use, convenient, and allow for self-administration at home are gaining popularity. This is particularly important in the context of the aging population and the need for long-term medication management.

Opportunities

• Focus on Personalized Medicine

The shift towards personalized medicine, which aims to tailor treatments to individual patients based on their genetic makeup and specific disease characteristics, is driving the demand for targeted drug delivery systems. These systems enable the delivery of drugs to specific sites in the body, maximizing therapeutic efficacy while minimizing side effects.

• Increasing R&D Investments

Pharmaceutical companies and research institutions are investing heavily in research and development of novel drug delivery technologies. This is driven by the need for improved drug delivery systems that can overcome the limitations of conventional oral or injectable formulations, such as poor bioavailability, drug degradation, and patient non-compliance.

Restraints/Challenges

• Regulatory Hurdles

The pharmaceutical industry is highly regulated, and getting approval for new drug delivery systems can be a lengthy and expensive process. Regulatory agencies such as the FDA in the United States impose strict requirements for safety and efficacy, which can delay the introduction of new drug delivery technologies.

• Intellectual Property Issues

Protecting intellectual property rights is crucial in the pharmaceutical and drug delivery sectors. Companies may face challenges in patenting their innovations and may encounter legal disputes with competitors over intellectual property rights.

This drug delivery market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the drug delivery market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In March 2022, Sandoz, a Novartis division, announced the acquisition of a UK-based medical and drug delivery device company, Coalesce Product Development Limited. Sandoz acquired Coalesce's expertise and assets as part of the arrangement, which will help the company expand its respiratory medication portfolio and improve patient access to high-quality, complex therapeutics

Asia-Pacific Drug Delivery Market Scope

The drug delivery market is segmented on the basis of product type, application, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Oral Drug Delivery
• Pulmonary Drug Delivery
• Injectable Drug Delivery
• Ophthalmic Drug Delivery
• Nasal Drug Delivery
• Topical Drug Delivery
• Implantable Drug Delivery
• Transmucosal Drug Delivery

Application

• Cancer
• Diabetes
• Respiratory Diseases
• Cardiovascular Diseases
• Others

 End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Asia-Pacific Drug Delivery Market Regional Analysis/Insights

The drug delivery market is analysed and market size insights and trends are provided by product type, application, end-users and distribution channel as referenced above.

The countries covered in the drug delivery market report are China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, and Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC).

China dominates the drug delivery market because of the strong base of healthcare facilities, strong presence of major players in the market, rising demand of the drug delivery products and rising number of research activities in this region.   

China is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, rise in medical tourism, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The drug delivery market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for Drug delivery market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Drug delivery market. The data is available for historic period 2015 to 2020.

Competitive Landscape and Drug Delivery Market Share Analysis

The drug delivery market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the company's focus related to drug delivery market.

Some of the major players operating in the drug delivery market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd.(Israel)
• Sanofi (France), Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Novartis AG (Switzerland)
• Sun Pharmaceutical Industries Ltd. (India)
• Dr. Reddy's Laboratories Ltd. (India)
• Bausch Health Companies Inc. (Canada)
• AstraZeneca (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Merck & Co., Inc. (U.S.)
• Cadila Pharmaceuticals. (India)
• 3M (U.S.)
• Bayer AG (Germany)
• Astellas Pharma Inc. (Japan)
• AbbVie Inc. (U.S.)
• Takeda Pharmaceutical Company Limited (Japan)